• 1
    Wang TL, Yap IL, Tan YO. Hepatocellular carcinoma—a case series of 104 patients. Ann Acad Med Singapore 1991; 20:215218.MEDLINE
  • 2
    Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, Nakajima Y, et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 1985; 56:918928.MEDLINE
  • 3
    Simonetti RG, Liberati A, Angiolini C, Pagliaro L. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997; 8:117136.MEDLINE
  • 4
    Villa E, Dugani A, Fantoni E, Camellini L, Buttafoco P, Grottola A, Pompei G, et al. Type of estrogen receptor determines response to antiestrogen therapy. Cancer Res 1996; 56:38833885.MEDLINE
  • 5
    Boix L, Bruix J, Castells A, Fuster J, Bru C, Visa J, Rivera F, et al. Sex hormone receptors in hepatocellular carcinoma. Is there a rationale for hormonal treatment? J Hepatol 1993; 17:187191.MEDLINE
  • 6
    Chow PK, Soo K. Hormonal therapy on hepatocellular carcinoma: the current scientific and clinical evidence. Asian J Surg 2000; 23:5663.
  • 7
    Chow PK, Huynh H, Khin LW, Ooi PJ, Ong HS, Soo KC. Therapeutic implications of the loss of estrogen receptor alpha and over-expression of androgen receptors in resected hepatocellular carcinoma. Aust N Z J Surg 2000; 70:95.MEDLINE
  • 8
    Chow PK, Hung H, Soo KC. Estrogen receptor status in inoperable hepatocellular carcinoma. Am J Gastroenterol 2001; 96:12971298.MEDLINE
  • 9
    Farinati F, De Maria N, Fornasiero A, Salvagnini M, Fagiuoli S, Chiaramonte M, Naccarato R. Prospective controlled trial with antiestrogen drug tamoxifen in patients with unresectable hepatocellular carcinoma. Dig Dis Sci 1992; 37:659662.MEDLINE
  • 10
    Martinez Cerezo FJ, Tomas A, Donoso L, Enriquez J, Guarner C, Balanzo J, Martinez Nogueras A, et al. Controlled trial of tamoxifen in patients with advanced hepatocellular carcinoma. J Hepatol 1994; 20:702706.MEDLINE
  • 11
    Elba S, Giannuzzi V, Misciagna G, Manghisi OG. Randomized controlled trial of tamoxifen versus placebo in inoperable hepatocellular carcinoma. Ital J Gastroenterol 1994; 26:6668.MEDLINE
  • 12
    Castells A, Bruix J, Bru C, Ayuso C, Roca M, Boix L, Vilana R, et al. Treatment of hepatocellular carcinoma with tamoxifen: a double-blind placebo-controlled trial in 120 patients. Gastroenterology 1995; 109:917922.MEDLINE
  • 13
    Tamoxifen in treatment of hepatocellular carcinoma: a randomised controlled trial. CLIP Group (Cancer of the Liver Italian Programme). Lancet 1998; 352:1720.MEDLINE
  • 14
    Perrone F, Gallo C, Daniele B, Gaeta GB, Izzo F, Capuano G, Adinolfi LE, et al. Tamoxifen in the treatment of hepatocellular carcinoma: 5-year results of the CLIP-1 multi-centre randomised controlled trial. Curr Pharm Des 2002; 8:10131019.MEDLINE
  • 15
    Gelmann EP. Tamoxifen for the treatment of malignancies other than breast and endometrial carcinoma. Semin Oncol 1997; 24 (Suppl 1): S1–65S1–70.MEDLINE
  • 16
    Jiang SY, Shyu RY, Yeh MY, Jordan VC. Tamoxifen inhibits hepatoma cell growth through an estrogen receptor independent mechanism. J Hepatol 1995; 23:712719.MEDLINE
  • 17
    Cheng AL, Chuang SE, Fine RL, Yeh KH, Liao CM, Lay JD, Chen DS. Inhibition of the membrane translocation and activation of protein kinase C, and potentiation of doxorubicin-induced apoptosis of hepatocellular carcinoma cells by tamoxifen. Biochem Pharmacol 1998; 55:523531.MEDLINE
  • 18
    Chow P, Kiat TC, Choo TB, Machin D. Tamoxifen in hepatocellular carcinoma. Lancet 1998; 352:819820.MEDLINE
  • 19
    Tan CK, Chow PK, Findlay M, Wong C, Machin D. Use of tamoxifen in hepatocellular carcinoma: a review and paradigm shift. J Gastroenterol Hepatol 2000; 15:725729.MEDLINE
  • 20
    Manesis EK, Giannoulis G, Zoumboulis P, Vafiadou I, Hadziyannis SJ. Treatment of hepatocellular carcinoma with combined suppression and inhibition of sex hormones: a randomized, controlled trial. Hepatology 1995; 21:15351542.MEDLINE
  • 21
    Machin D, Campbell M, Fayers P, Pinol APY. Sample size tables for clinical studies. Oxford: Blackwell, 1997.
  • 22
    EORTC QLQ-C30 Scoring Manual. Brussels, Belgium: European Organization for Research and Treatment of Cancer, 1995.
  • 23
    Parmar MKB, Machin D. Survival analysis: a practical approach. Chichester: Wiley, 1995.
  • 24
    Peyrade F, Frenay M, Etienne MC, Ruch F, Guillemare C, Francois E, Namer M, et al. Age-related difference in tamoxifen disposition. Clin Pharmacol Ther 1996; 59:401410.MEDLINE